FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362525411> ?p ?o ?g. }

• W4362525411 abstract "<div>Purpose:<p>Mistletoe extract (ME) is widely used for patients with cancer to support therapy and to improve quality of life (QoL). However, its use is controversial due to suboptimal trials and a lack of data supporting its intravenous administration.</p>Materials and Methods:<p>This phase I trial of intravenous mistletoe (Helixor M) aimed to determine the recommended phase II dosing and to evaluate safety. Patients with solid tumor progressing on at least one line of chemotherapy received escalating doses of Helixor M three times a week. Assessments were also made of tumor marker kinetics and QoL.</p>Results:<p>Twenty-one patients were recruited. The median follow-up duration was 15.3 weeks. The MTD was 600 mg. Treatment-related adverse events (AE) occurred in 13 patients (61.9%), with the most common being fatigue (28.6%), nausea (9.5%), and chills (9.5%). Grade 3+ treatment-related AEs were noted in 3 patients (14.8%). Stable disease was observed in 5 patients who had one to six prior therapies. Reductions in baseline target lesions were observed in 3 patients who had two to six prior therapies. Objective responses were not observed. The disease control rate (percentage of complete/partial response and stable disease) was 23.8%. The median stable disease was 15 weeks. Serum cancer antigen-125 or carcinoembryonic antigen showed a slower rate of increase at higher dose levels. The median QoL by Functional Assessment of Cancer Therapy-General increased from 79.7 at week 1 to 93 at week 4.</p>Conclusions:<p>Intravenous mistletoe demonstrated manageable toxicities with disease control and improved QoL in a heavily pretreated solid tumor population. Future phase II trials are warranted.</p>Significance:<p>Although ME is widely used for cancers, its efficacy and safety are uncertain. This first phase I trial of intravenous mistletoe (Helixor M) aimed to determine phase II dosing and to evaluate safety. We recruited 21 patients with relapsed/refractory metastatic solid tumor. Intravenous mistletoe (600 mg, 3/week) demonstrated manageable toxicities (fatigue, nausea, and chills) with disease control and improved QoL. Future research can examine ME's effect on survival and chemotherapy tolerability.</p></div>" @default.
• W4362525411 created "2023-04-06" @default.
• W4362525411 creator A5016491987 @default.
• W4362525411 creator A5018353497 @default.
• W4362525411 creator A5018401879 @default.
• W4362525411 creator A5020031098 @default.
• W4362525411 creator A5024413271 @default.
• W4362525411 creator A5024730570 @default.
• W4362525411 creator A5030498626 @default.
• W4362525411 creator A5030814481 @default.
• W4362525411 creator A5031348375 @default.
• W4362525411 creator A5033720986 @default.
• W4362525411 creator A5050789569 @default.
• W4362525411 creator A5060219345 @default.
• W4362525411 creator A5062219338 @default.
• W4362525411 creator A5066848628 @default.
• W4362525411 creator A5081724410 @default.
• W4362525411 creator A5081913427 @default.
• W4362525411 creator A5090143508 @default.
• W4362525411 creator A5087089024 @default.
• W4362525411 date "2023-04-04" @default.
• W4362525411 modified "2023-09-25" @default.
• W4362525411 title "Data from Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer" @default.
• W4362525411 doi "https://doi.org/10.1158/2767-9764.c.6551064" @default.
• W4362525411 hasPublicationYear "2023" @default.
• W4362525411 type Work @default.
• W4362525411 citedByCount "0" @default.
• W4362525411 crossrefType "posted-content" @default.
• W4362525411 hasAuthorship W4362525411A5016491987 @default.
• W4362525411 hasAuthorship W4362525411A5018353497 @default.
• W4362525411 hasAuthorship W4362525411A5018401879 @default.
• W4362525411 hasAuthorship W4362525411A5020031098 @default.
• W4362525411 hasAuthorship W4362525411A5024413271 @default.
• W4362525411 hasAuthorship W4362525411A5024730570 @default.
• W4362525411 hasAuthorship W4362525411A5030498626 @default.
• W4362525411 hasAuthorship W4362525411A5030814481 @default.
• W4362525411 hasAuthorship W4362525411A5031348375 @default.
• W4362525411 hasAuthorship W4362525411A5033720986 @default.
• W4362525411 hasAuthorship W4362525411A5050789569 @default.
• W4362525411 hasAuthorship W4362525411A5060219345 @default.
• W4362525411 hasAuthorship W4362525411A5062219338 @default.
• W4362525411 hasAuthorship W4362525411A5066848628 @default.
• W4362525411 hasAuthorship W4362525411A5081724410 @default.
• W4362525411 hasAuthorship W4362525411A5081913427 @default.
• W4362525411 hasAuthorship W4362525411A5087089024 @default.
• W4362525411 hasAuthorship W4362525411A5090143508 @default.
• W4362525411 hasConcept C121608353 @default.
• W4362525411 hasConcept C126322002 @default.
• W4362525411 hasConcept C141071460 @default.
• W4362525411 hasConcept C159110408 @default.
• W4362525411 hasConcept C197934379 @default.
• W4362525411 hasConcept C2776694085 @default.
• W4362525411 hasConcept C2777288759 @default.
• W4362525411 hasConcept C2777387746 @default.
• W4362525411 hasConcept C2778594517 @default.
• W4362525411 hasConcept C2779951463 @default.
• W4362525411 hasConcept C2780580376 @default.
• W4362525411 hasConcept C71924100 @default.
• W4362525411 hasConcept C90924648 @default.
• W4362525411 hasConceptScore W4362525411C121608353 @default.
• W4362525411 hasConceptScore W4362525411C126322002 @default.
• W4362525411 hasConceptScore W4362525411C141071460 @default.
• W4362525411 hasConceptScore W4362525411C159110408 @default.
• W4362525411 hasConceptScore W4362525411C197934379 @default.
• W4362525411 hasConceptScore W4362525411C2776694085 @default.
• W4362525411 hasConceptScore W4362525411C2777288759 @default.
• W4362525411 hasConceptScore W4362525411C2777387746 @default.
• W4362525411 hasConceptScore W4362525411C2778594517 @default.
• W4362525411 hasConceptScore W4362525411C2779951463 @default.
• W4362525411 hasConceptScore W4362525411C2780580376 @default.
• W4362525411 hasConceptScore W4362525411C71924100 @default.
• W4362525411 hasConceptScore W4362525411C90924648 @default.
• W4362525411 hasLocation W43625254111 @default.
• W4362525411 hasOpenAccess W4362525411 @default.
• W4362525411 hasPrimaryLocation W43625254111 @default.
• W4362525411 hasRelatedWork W1561626714 @default.
• W4362525411 hasRelatedWork W1969600685 @default.
• W4362525411 hasRelatedWork W2007960806 @default.
• W4362525411 hasRelatedWork W2050480145 @default.
• W4362525411 hasRelatedWork W2581074245 @default.
• W4362525411 hasRelatedWork W2897258609 @default.
• W4362525411 hasRelatedWork W2982017689 @default.
• W4362525411 hasRelatedWork W4284891694 @default.
• W4362525411 hasRelatedWork W4319728721 @default.
• W4362525411 hasRelatedWork W4361215268 @default.
• W4362525411 isParatext "false" @default.
• W4362525411 isRetracted "false" @default.
• W4362525411 workType "article" @default.